TrialThe Journal of infectious diseases2024

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.

Christine A Shaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.